Epidemiology and Biomarker Study in Alzheimer's Disease

Part of paid clinical trials in Houston, Texas.

Sponsor
Eli Lilly and Company
Study ID
NCT07142954
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
55 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • P-tau217 Test — OTHER
    A plasma test measuring phosphorylated tau at Position 217 (P-tau217).

Study Details

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Key Dates

Start date
Aug 25, 2025
Status verified
May 2026
Primary completion
Jul 31, 2033
Completion
Jul 31, 2033

Study Design

Enrollment
3,400 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Elevated Plasma P-tau217 Levels
    Participants with known elevated plasma P-tau217 levels who are cognitively unimpaired at baseline per self-report.
  • Other: Not-Elevated P-tau217 Levels
    Participants with known not-elevated plasma P-tau217 levels who are cognitively unimpaired at baseline per self-report.

Primary Outcome Measure

Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components [ Time Frame: Baseline up to 7 years ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Care Access - HoustonHoustonTexas77054
877-791-0656
Ali Bajwa (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Care Access - Houston· Houston, TX

Related Studies